Status:
COMPLETED
Sublingual Cockroach Safety in Adults With Cockroach Allergy & Perennial Allergic Rhinitis With or Without Asthma
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsors:
Inner-City Asthma Consortium
Conditions:
Allergy
Asthma
Eligibility:
All Genders
5-55 years
Phase:
PHASE1
Brief Summary
Immunotherapy may help reduce symptoms of allergy and asthma. Problems concerning compliance and adverse events with subcutaneous allergen immunotherapy have generated interest in delivering immunothe...
Detailed Description
The prevalence of asthma has dramatically increased in many parts of the world. Currently, there is no effective way to prevent development of allergic rhinitis and asthma and no cure. Sublingual immu...
Eligibility Criteria
Inclusion
- Inclusion Criteria for All Participants:
- History of perennial allergic rhinitis with or without asthma for a minimum of 1 year prior to study entry
- Positive skin prick test to German cockroach performed along with negative (saline) and positive (histamine) controls
- Willing to sign EpiPen training form
- Parent or guardian willing to provide informed consent, if applicable
- Inclusion Criteria for Participants with Asthma:
- Diagnosis of well-controlled, mild to moderate persistent asthma, defined as having symptoms at least 3 times a week with no controller medication OR less than 3 times a week on controller medication. More information about this criterion can be found in the protocol.
- Diagnosis of asthma made over 1 year prior to study entry
- Exclusion Criteria:
- Have severe, persistent asthma (according to National Asthma Education and Prevention Program \[NAEPP\] classification) as evidenced by those who require a dose of greater than 500 mcg of fluticasone/day or equivalent of another inhaled corticosteroid OR who have been hospitalized for asthma within 6 months prior to study entry
- Life-threatening asthma exacerbation requiring intubation or mechanical ventilation or resulting in a hypoxic seizure in the 2 years prior to study entry
- History of anaphylaxis of Grade 2 or higher as defined in the protocol
- Unstable angina, significant arrhythmia, uncontrolled hypertension, or other chronic or immunologic diseases that, in the opinion of the investigator, may interfere with the study or pose additional risk to the patient. More information about this criterion can be found in the protocol.
- Taking medications that could induce gastrointestinal reactions during the study. Participants taking such medications must prove to be stable with no side effects for at least 3 months prior to study screening to be considered eligible.
- Received an investigational drug in the 30 days prior to study entry OR plan to receive an investigational drug during the study
- Received allergen immunotherapy in the 180 days prior to screening or plan to initiate or resume allergen immunotherapy during the study
- Taking tricyclic antidepressants or beta-adrenergic blocker drugs
- Received omalizumab in the 3 months prior to study screening
- Known contraindication to therapy with cockroach extract used in this study
- Mental illness that would interfere with the participant's ability to comply to study requirements
- History of drug or alcohol abuse that, in the opinion of the investigator, would interfere with the study
- Plan to leave study area during the study
- Does not primarily speak English, including caretakers of participants when the participant is a child
- Cannot perform spirometry
- Pregnant or breastfeeding
Exclusion
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00434421
Start Date
February 1 2007
End Date
August 1 2009
Last Update
June 11 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University School of Medicine, 600 North Wolfe St, CMSC 1102
Baltimore, Maryland, United States, 21287